Drug Trial Radar · NCT04630366
A Phase 1, First Time in Humans Study of NST-1024
Last checked: Nov 19, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Oct 27, 2020
Primary completion
Jun 20, 2022
Study completion Jun 20, 2022
Sponsor
- Lead sponsor
- NorthSea Therapeutics B.V.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A first time in man study of NST-1024
Conditions
- Hypertriglyceridemia
Interventions
NST-1024Drug
NST-1024
PlaceboDrug
Matching placebo to NST-1024
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Leeds Clinical Research Unit
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.